Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond.

Autor:	Rodriguez A; Department of Neurosurgery, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States., Ahluwalia MS; Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, United States., Bettegowda C; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, United States., Brem H; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, United States., Carter BS; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States., Chang S; Division of Neuro-Oncology, Department of Neurosurgery, University of California San Francisco, San Francisco, CA, United States., Das S; Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada., Eberhart C; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Garzon-Muvdi T; Department of Neurosurgery, Emory University, Atlanta, GA, United States., Hadjipanayis CG; Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States., Hawkins C; Division of Pathology, Hospital for Sick Children, Toronto, ON, Canada., Jacques TS; Developmental Biology and Cancer Programme, UCL GOS Institute of Child Health and Department of Histopathology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom., Khalessi AA; Department of Radiology and Neurosciences, Don and Karen Cohn Chancellor's Endowed Chair of Neurological Surgery, University of California, San Diego, San Diego, CA, United States., McDermott MW; Division of Neurosurgery, Miami Neuroscience Institute, Miami, FL, United States., Mikkelsen T; Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, United States., Orr BA; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, United States., Phillips JJ; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States.; Neuropathology Division, Department of Pathology, University of California, San Francisco, San Francisco, CA, United States., Rosenblum M; Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, United States., Shelton WJ; Department of Neurosurgery, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States., Solomon DA; Division of Neuropathology, Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States., von Deimling A; Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany., Woodworth GF; Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, United States., Rutka JT; Division of Neurosurgery, Chair Emeritus, Hospital for Sick Children, Toronto, ON, Canada.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Sep 23; Vol. 14, pp. 1471257. Date of Electronic Publication: 2024 Sep 23 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1471257
Abstrakt:	Implementation of standardized protocols in neurooncology during the surgical resection of brain tumors is needed to advance the clinical treatment paradigms that use tissue for diagnosis, prognosis, bio-banking, and treatment. Currently recommendations on intraoperative tissue procurement only exist for diffuse gliomas but management of other brain tumor subtypes can also benefit from these protocols. Fresh tissue from surgical resection can now be used for intraoperative diagnostics and functional precision medicine assays. A multidisciplinary neuro-oncology perspective is critical to develop the best avenues for practical standardization. This perspective from the multidisciplinary Oncology Tissue Advisory Board (OTAB) discusses current advances, future directions, and the imperative of adopting standardized protocols for diverse brain tumor entities. There is a growing need for consistent operating room practices to enhance patient care, streamline research efforts, and optimize outcomes. Competing Interests: The authors, except WJS, are members of an advisory board sponsored by Nico Corporation. However, Nico Corporation was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. CB is a consultant for Depuy-Synthes, Bionaut Labs, Haystack Oncology and Privo Technologies. CB is a co-founder of OrisDx and Belay Diagnostics. HB is a chairman of the Medical Advisory Board for Insightec. Insightec is developing focused ultrasound treatments for brain tumors. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. HB has consultation agreements with Insightec, Candel Therapeutics, Inc., Catalio Nexus Fund II, LLC, LikeMinds, Inc*, and Nurami Medical*, Intragel *includes equity or options. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Rodriguez, Ahluwalia, Bettegowda, Brem, Carter, Chang, Das, Eberhart, Garzon-Muvdi, Hadjipanayis, Hawkins, Jacques, Khalessi, McDermott, Mikkelsen, Orr, Phillips, Rosenblum, Shelton, Solomon, von Deimling, Woodworth and Rutka.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu